HomeCompareENDP vs CL

ENDP vs CL: Dividend Comparison 2026

ENDP yields 534.19% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENDP wins by $102783.24M in total portfolio value
10 years
ENDP
ENDP
● Live price
534.19%
Share price
$0.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102783.28M
Annual income
$75,120,205,270.55
Full ENDP calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — ENDP vs CL

📍 ENDP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENDPCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENDP + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENDP pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENDP
Annual income on $10K today (after 15% tax)
$45,405.98/yr
After 10yr DRIP, annual income (after tax)
$63,852,174,479.97/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, ENDP beats the other by $63,852,169,846.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENDP + CL for your $10,000?

ENDP: 50%CL: 50%
100% CL50/50100% ENDP
Portfolio after 10yr
$51391.66M
Annual income
$37,560,105,361.13/yr
Blended yield
73.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ENDP right now

ENDP
Analyst Ratings
24
Buy
20
Hold
4
Sell
Consensus: Buy
Price Target
$2.00
+434.2% upside vs current
Range: $2.00 — $2.00
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENDP buys
0
CL buys
0
No recent congressional trades found for ENDP or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENDPCL
Forward yield534.19%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$102783.28M$41.0K
Annual income after 10y$75,120,205,270.55$5,451.69
Total dividends collected$100415.31M$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$2.00$92.45

Year-by-year: ENDP vs CL ($10,000, DRIP)

YearENDP PortfolioENDP Income/yrCL PortfolioCL Income/yrGap
1← crossover$64,119$53,418.80$11,014$313.84+$53.1KENDP
2$388,715$320,107.45$12,200$415.44+$376.5KENDP
3$2,229,591$1,813,666.47$13,607$553.09+$2.22MENDP
4$12,107,940$9,722,278.04$15,301$741.41+$12.09MENDP
5$62,298,925$49,343,428.51$17,374$1,002.00+$62.28MENDP
6$303,936,946$237,277,096.11$19,958$1,367.44+$303.92MENDP
7$1,407,082,298$1,081,869,766.45$23,243$1,887.87+$1407.06MENDP
8$6,186,454,865$4,680,876,806.01$27,512$2,642.43+$6186.43MENDP
9$25,853,337,136$19,233,830,430.18$33,197$3,759.22+$25853.30MENDP
10$102,783,276,006$75,120,205,270.55$40,973$5,451.69+$102783.24MENDP

ENDP vs CL: Complete Analysis 2026

ENDPStock

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Full ENDP Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this ENDP vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENDP vs SCHDENDP vs JEPIENDP vs OENDP vs KOENDP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.